BOSTON / Apr 30, 2024 / Business Wire / 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended March 31, 2024.
"We had a solid start to the year with topline revenue of $10 million for the first quarter and continued to see robust demand for our handheld devices as applications for chemical detection and identification at the point of need gain further traction in the US and internationally," said Kevin J. Knopp, CEO and Co-founder. "This morning, we were excited to announce the acquisition of RedWave Technology which we believe will be a very strong strategic fit as we execute against our existing initiatives for the near- and long-term."
Recent Highlights
First Quarter 2024 Financial Results
Revenue was $10.0 million for the three months ended March 31, 2024, a 5% increase over the prior year period. This was primarily driven by an increase in handheld devices revenue offset by a decrease in desktop devices revenue. The installed base grew to 2,914 devices with 53 handheld devices and 8 desktop devices placed during the first quarter 2024. Recurring revenue represented 45% of total revenues in the quarter.
Gross profit was $5.0 million for the first quarter of 2024, compared to $4.4 million for the corresponding prior year period. Gross margin was 50% as compared to 46% for the corresponding prior year period.
Operating expenses were $17.7 million for the first quarter of 2024, compared to $17.4 million for the corresponding prior year period. This increase was driven by stock-based compensation and legal fees related to our acquisition, offset in part by a reduction in third party commissions and salary and related costs.
Net loss was $10.9 million for the first quarter of 2024, compared to $12.5 million for the corresponding prior year period. Net loss per share was $0.33 for the first quarter of 2024, compared to a net loss per share of $0.39 for the corresponding prior year period.
Cash, cash equivalents and marketable securities were $134.2 million as of March 31, 2024 with no debt outstanding. Subsequent to quarter end, the Company used $45 million of cash as part of the acquisition of RedWave Technology. The Company anticipates that its cash on hand continues to be sufficient to reach cash flow breakeven.
2024 Guidance
908 Devices now expects full year reported 2024 revenue to be in the range of $63.0 million to $65.0 million, representing 25% to 29% growth over full year 2023. This includes $11 million of expected revenue from RedWave Technology, representing 8 months of ownership.
Webcast Information
908 Devices will host a conference call to discuss the first quarter 2024 financial results before market open on Tuesday, April 30, 2024 at 5:30 am Pacific Time / 8:30 am Eastern Time. A webcast of the conference call can be accessed at https://ir.908devices.com/news-events/events. The webcast will be archived and available for replay for at least 90 days after the event.
About 908 Devices
908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.
Forward Looking Statements
This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth, including the expected revenue contribution from RedWave. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
908 DEVICES INC. Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) (unaudited) | ||||||
|
|
|
|
|
|
|
|
| Three Months Ended | ||||
|
| March 31, | ||||
|
| 2024 |
| 2023 | ||
Revenue: |
|
|
|
|
|
|
Product revenue |
| $ | 7,233 |
| $ | 7,022 |
Service revenue |
|
| 2,758 |
|
| 2,240 |
Contract revenue |
|
| — |
|
| 225 |
Total revenue |
|
| 9,991 |
|
| 9,487 |
Cost of revenue: |
|
|
|
|
|
|
Product cost of revenue |
|
| 3,210 |
|
| 3,786 |
Service cost of revenue |
|
| 1,778 |
|
| 1,270 |
Contract cost of revenue |
|
| — |
|
| 47 |
Total cost of revenue |
|
| 4,988 |
|
| 5,103 |
Gross profit |
|
| 5,003 |
|
| 4,384 |
Operating expenses: |
|
|
|
|
|
|
Research and development |
|
| 5,790 |
|
| 5,398 |
Selling, general and administrative |
|
| 11,901 |
|
| 12,003 |
Total operating expenses |
|
| 17,691 |
|
| 17,401 |
Loss from operations |
|
| (12,688) |
|
| (13,017) |
Other income: |
|
|
|
|
|
|
Other income, net |
|
| 1,701 |
|
| 485 |
Loss from operations before income taxes |
|
| (10,987) |
|
| (12,532) |
Benefit for income taxes |
|
| 70 |
|
| — |
Net loss |
| $ | (10,917) |
| $ | (12,532) |
|
|
|
|
|
|
|
Net loss per share attributable to common stockholders |
| $ | (0.33) |
| $ | (0.39) |
Weighted average common shares outstanding |
|
| 32,710,894 |
|
| 31,965,799 |
908 DEVICES INC. Condensed Consolidated Balance Sheets (in thousands) (unaudited) | ||||||
|
|
|
|
|
|
|
|
| March 31, |
| December 31, | ||
|
| 2024 |
| 2023 | ||
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash, cash equivalents and marketable securities |
| $ | 134,195 |
| $ | 145,682 |
Accounts receivable, net |
|
| 7,486 |
|
| 8,989 |
Inventory |
|
| 16,356 |
|
| 14,938 |
Prepaid expenses and other current assets |
|
| 3,831 |
|
| 4,181 |
Total current assets |
|
| 161,868 |
|
| 173,790 |
Operating lease, right-of-use assets |
|
| 5,754 |
|
| 6,233 |
Property and equipment, net |
|
| 3,215 |
|
| 3,342 |
Goodwill |
|
| 10,139 |
|
| 10,367 |
Intangible, net |
|
| 7,468 |
|
| 7,860 |
Other long-term assets |
|
| 1,347 |
|
| 1,389 |
Total assets |
| $ | 189,791 |
| $ | 202,981 |
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable and accrued expenses |
| $ | 6,771 |
| $ | 9,904 |
Deferred revenue |
|
| 10,483 |
|
| 10,629 |
Operating lease liabilities |
|
| 2,076 |
|
| 2,016 |
Total current liabilities |
|
| 19,330 |
|
| 22,549 |
Deferred revenue, net of current portion |
|
| 7,871 |
|
| 8,571 |
Other long-term liabilities |
|
| 5,697 |
|
| 6,370 |
Total liabilities |
|
| 32,898 |
|
| 37,490 |
Total stockholders' equity |
|
| 156,893 |
|
| 165,491 |
Total liabilities and stockholders' equity |
| $ | 189,791 |
| $ | 202,981 |
| Last Trade: | US$2.06 |
| Daily Change: | 0.12 6.19 |
| Daily Volume: | 477,560 |
| Market Cap: | US$71.730M |
December 19, 2024 November 12, 2024 August 06, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
